Navigation Links
Enzyme explains angina in diabetics
Date:11/27/2012

In a new study published in the scientific journal Circulation, scientists at Karolinska Institutet and Karolinska University Hospital in Sweden show that an enzyme called arginase might have a key part to play in the development of cardiovascular disease in patients who already have type II diabetes. According to the team, arginase prevents the formation of protective nitrogen oxide in the blood vessels, and treatments that inhibit this enzyme reduce the risk of angina in diabetics.

"The fact that we could demonstrate the presence of arginase in several types of cell in the vessel wall gives us an entirely new explanatory model for the development of complications in these patients," says lead investigator Professor John Pernow.

Complications in diabetes patients result from constrictions of the blood vessels caused by plaque deposits on the vessel walls (atherosclerosis). The ensuing reduction in blood flow and oxygen supply can lead to angina, myocardial infarction or stroke, and possible amputation. Atherosclerosis is more common in people who smoke and who have high levels of blood lipids, although the risk is most pronounced in patients with diabetes. The reason for this correlation between diabetes and cardiovascular disease has largely eluded scientists and there is still no specific treatment for these complications.

In this present study, the researchers analysed the function of the arginase enzyme (or protein) in the blood vessels of patients with both type II diabetes and angina and found that it prevents the formation of protective molecule nitric oxide in the vessel wall. After introducing a substance already known to inhibit the enzyme, they observed a significant improvement in blood vessel function in these patients.

A comparative analysis showed that the arginase inhibitor did not have the same positive effect on patients with angina but without type II diabetes, and had no effect at all on healthy controls.

"Nitric oxide has a very important function to perform in the vessel walls," says Professor Pernow. "Apart from dilating them, it prevents the formation of plaque. For some reason, however, the mechanism is impaired in people with diabetes."

A total of 48 patients were included in the study and the team is now planning a larger follow-up study to confirm their results and develop treatments using arginase inhibitors. The study was financed by the Swedish Research Council, the Swedish Heart-Lung Foundation, the NovoNordisk Foundation, the European Foundation for the Study of Diabetes, and the Gustav V and Queen Victoria Foundation.


'/>"/>

Contact: Press Office
pressinfo@ki.se
46-852-486-077
Karolinska Institutet
Source:Eurekalert

Related medicine news :

1. Gateway enzyme for chemicals from catnip to cancer drug
2. Structure of enzyme unravelled providing basis for more accurate design of chemotherapeutic drugs
3. Mayo Clinic researchers identify new enzyme to fight Alzheimers disease
4. Compounds activate key cancer enzyme to interfere with tumor formation
5. Enzymes implicated in disease processes attack one another instead of harming body proteins
6. Clemson researchers collect and reuse enzymes while maintaining bioactivity
7. Enzyme offers new therapeutic target for cancer drugs
8. Enzyme corrects more than 1 million faults in DNA replication
9. Discovery explains how cellular pathways converge to regulate food intake and body weight
10. Inherited DNA change explains overactive leukemia gene
11. Psychological Science explains uproar over prostate-cancer screenings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... PharmMD ... Counsel. Garrett will focus on contract negotiations, corporate strategy and healthcare data law. ... and best practices in data breaches for the Part D Star Rating improvement ...
(Date:2/11/2016)... ... February 11, 2016 , ... Greenfield Insurance Group in ... to assist the people of their local community. The agency pledges to select ... leaders. Their hope is to bring awareness to important local causes with fundraising ...
(Date:2/11/2016)... Island, NY (PRWEB) , ... February 11, 2016 ... ... has enhanced and updated its hallmark resource, Infusion Therapy Standards of Practice, to ... leader in vein illumination with an estimated 85% share of the market, facilitates ...
(Date:2/11/2016)... ... February 11, 2016 , ... Duterte ... community involvement program, introduces a new charity campaign to raise funds for Ronald ... being accepted at https://donate.rmhc.org/ . , Ronald McDonald House (RMH) is an ...
(Date:2/11/2016)... ... 2016 , ... The annual list showcases the 20 Most Promising SharePoint Solution ... dedication and commitment to the SharePoint ecosystem. A panel of experts and members of ... to recognize and promote technology entrepreneurship. , The survey was made at the ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... AAIPharma Services Corp./Cambridge Major Laboratories, Inc. ... development services for the pharmaceutical and biotechnology industries, ... in its Charleston, SC ... recent investments. Charleston ... with small-scale lyophilization. The site has invested in ...
(Date:2/11/2016)... , 11 de fevereiro de 2016  A ... sua fábrica de soroalbumina bovina (BSA -- ... fábrica fica na Ilha Norte da Nova Zelândia, ... e estabelecido na fábrica da Proliant nos EUA, ... O projeto e instalação dos equipamentos foram feitos ...
(Date:2/11/2016)... Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 ... breast cancer market will experience considerable expansion from $1.9 billion ... Annual Growth Rate (CAGR) of 8.5%. --> Breast ... that the Asia-Pacific (APAC) breast cancer ... to $3.4 billion by 2021, at a Compound Annual Growth ...
Breaking Medicine Technology: